These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15618407)

  • 1. Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.
    Renaud EJ; MacLaughlin DT; Oliva E; Rueda BR; Donahoe PK
    Proc Natl Acad Sci U S A; 2005 Jan; 102(1):111-6. PubMed ID: 15618407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
    Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
    Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
    Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
    Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
    Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis.
    Namkung J; Song JY; Jo HH; Kim MR; Lew YO; Donahoe PK; MacLaughlin DT; Kim JH
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3224-30. PubMed ID: 22761458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
    Barbie TU; Barbie DA; MacLaughlin DT; Maheswaran S; Donahoe PK
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15601-6. PubMed ID: 14671316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
    Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
    Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
    Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
    Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
    Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
    Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
    Pieretti-Vanmarcke R; Donahoe PK; Pearsall LA; Dinulescu DM; Connolly DC; Halpern EF; Seiden MV; MacLaughlin DT
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17426-31. PubMed ID: 17088539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
    Segev DL; Ha TU; Tran TT; Kenneally M; Harkin P; Jung M; MacLaughlin DT; Donahoe PK; Maheswaran S
    J Biol Chem; 2000 Sep; 275(37):28371-9. PubMed ID: 10874041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
    Segev DL; Hoshiya Y; Hoshiya M; Tran TT; Carey JL; Stephen AE; MacLaughlin DT; Donahoe PK; Maheswaran S
    Proc Natl Acad Sci U S A; 2002 Jan; 99(1):239-44. PubMed ID: 11773638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand.
    Salhi I; Cambon-Roques S; Lamarre I; Laune D; Molina F; Pugnière M; Pourquier D; Gutowski M; Picard JY; Xavier F; Pèlegrin A; Navarro-Teulon I
    Biochem J; 2004 May; 379(Pt 3):785-93. PubMed ID: 14750901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a Müllerian-inhibiting substance autocrine/paracrine system in adult human endometrium.
    Wang J; Dicken C; Lustbader JW; Tortoriello DV
    Fertil Steril; 2009 Apr; 91(4):1195-203. PubMed ID: 18328480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.
    Hwang SJ; Suh MJ; Yoon JH; Kim MR; Ryu KS; Nam SW; Donahoe PK; Maclaughlin DT; Kim JH
    Int J Oncol; 2011 Oct; 39(4):811-20. PubMed ID: 21573503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism.
    Ha TU; Segev DL; Barbie D; Masiakos PT; Tran TT; Dombkowski D; Glander M; Clarke TR; Lorenzo HK; Donahoe PK; Maheswaran S
    J Biol Chem; 2000 Nov; 275(47):37101-9. PubMed ID: 10958795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung.
    Catlin EA; Tonnu VC; Ebb RG; Pacheco BA; Manganaro TF; Ezzell RM; Donahoe PK; Teixeira J
    Endocrinology; 1997 Feb; 138(2):790-6. PubMed ID: 9003016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
    Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
    Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of müllerian inhibiting substance specific binding in human cell lines.
    MacLaughlin DT; Levin RK; Catlin EA; Taylor LA; Preffer FI; Donahoe PK
    Horm Metab Res; 1992 Dec; 24(12):570-5. PubMed ID: 1478615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic studies of MIS signalling in sexual development.
    Jamin SP; Arango NA; Mishina Y; Behringer RR
    Novartis Found Symp; 2002; 244():157-64; discussion 164-8, 203-6, 253-7. PubMed ID: 11990789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.